Methods: 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands. Data were obtained retrospectively. EGFR mutation status was assessed by next-generation sequencing. Progression free survival (PFS), disease control rate (DCR) and objective response rate (ORR) were assessed using RECIST v1.1.
Van Veggel, B., Van Der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., ... De Langen, J. (2018). P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 13(10), S815. https://doi.org/10.1016/j.jtho.2018.08.1437